Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Hitherto unseen survival in an ALK-positive-patient withadvanced stage adult ganglioneuroblastoma treated withpersonalized medicine
Final published version, 65.7 KB, PDF document
Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.
Original language | English |
---|---|
Journal | Clinical Case Reports |
Volume | 5 |
Issue number | 12 |
Pages (from-to) | 2085-2087 |
Number of pages | 3 |
ISSN | 2050-0904 |
DOIs | |
Publication status | Published - Dec 2017 |
Number of downloads are based on statistics from Google Scholar and www.ku.dk
No data available
ID: 196371326